Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov:120:102624.
doi: 10.1016/j.ctrv.2023.102624. Epub 2023 Sep 7.

Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome

Linda Cucciniello  1 , Giovanna Garufi  2 , Rossana Di Rienzo  3 , Claudia Martinelli  3 , Giuliana Pavone  4 , Mario Giuliano  5 , Grazia Arpino  3 , Filippo Montemurro  6 , Lucia Del Mastro  7 , Michelino De Laurentiis  8 , Fabio Puglisi  9
Affiliations
Free article
Review

Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome

Linda Cucciniello et al. Cancer Treat Rev. 2023 Nov.
Free article

Abstract

Endocrine therapy is one of the standard adjuvant treatments to reduce the risk of recurrence and mortality in patients with hormone receptor positive early breast cancer. Despite its proven efficacy, ET side effects, which persist over time even if low grade, may deteriorate quality of life. During follow-up visits, emphasis is generally placed on the risk of disease recurrence, while the topic of ET side effects is commonly neglected and discussed only briefly. This could lead to poor adherence to therapy and early treatment discontinuation, resulting in worse survival outcomes. The aim of this review is to provide an overview of the available evidence on the incidence and reporting of ET-related side effects (including vasomotor symptoms, musculoskeletal disorders and genitourinary syndrome of menopause, as well as fatigue, psychological and ocular disorders, dysmetabolic effects and loss of bone density) and of the pharmacological and non-pharmacological strategies available to mitigate symptom burden.

Keywords: Adjuvant endocrine therapy; Early breast cancer; Endocrine toxicities; Multidisciplinary management.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: M.G. has served on the advisory boards for AstraZeneca, Daichii Sankyo, Exact Sciences, Lilly, MSD, Novartis, Pfizer, Roche, Seagen; has received travel grants from Roche, Celgene, Pfizer and research funding (to the institution) from Novartis and AstraZeneca. G.A. has receivedhonoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational eventsfrom Roche, Pfizer, Lilly, AstraZeneca, Novartis and Gilead; has received travel grants from Roche, Lilly, AstraZeneca and Gilead; has served on the advisory boards forRoche, Novartis, Lilly, Pfizer, MSD, Dompè, Pierre Fabre, Eisai, Sophos, Epionpharma, Gilead, Seagen, Astra Zeneca and Exact Science. F.M. has received fees for consultant/advisory role for Roche, AstraZeneca, Seagen, Novartis, Daichii Sankyo, MSD and Pierre Fabre; has received fees as speaker from AstraZeneca, Daichii Sankyo, MSD, Novartis, Pfizer and Eli Lilly; from May 15(th) 2023, he’s employed at F Hoffmann La Roche, Basel SW. L.D.M. has received personal fees from Eli Lilly, Novartis, Roche, MSD, Pfizer, Exact Sciences, Pierre Fabre, Daiichi Sankyo, AstraZeneca, Seagen, Eisai, Ipsen and Gilead.M.D.L. reports personal fees from Pfizer, Novartis, Roche, AstraZeneca, Eli Lilly, MSD, Daiichi-Sankyo, GSK, Sanofi, Celtrion, Organon and Seagen.F.P. has received honoraria for speakers’ bureaus, consultancy, advisory board from Amgen, Exact Sciences, Pierre-Fabre, Gilead, Pfizer, Celgene, GSK, Daiichi Sankyo, Ipsen, Seagen, Takeda, Eli Lilly, MSD, Novartis, AstraZeneca, Roche, Eisai, Viatris; research funding from AstraZeneca, Roche, Eisai. The remaining authors declare no competing interests. Funding declaration: this work was supported by the Italian Ministry of Health – Ricerca Corrente.

LinkOut - more resources